US-based Juno Therapeutics purchased a German biotech

12/05/2015 - 2 minutes

Juno Therapeutics has purchased Stage Cell Therapeutics, a privately held biotechnology company, based in Munich and Göttingen, Germany. The acquired technologies will support the development of the next generation CAR-T and TCR-T products, bringing Juno one step closer to beating cancer.

The transaction further underlines Juno’s strategy of becoming a world leader in process development and in the manufacturing of cellular therapies. The American company will have access to transformative cell selection and activation capabilities, next generation manufacturing automation technologies, enhanced control of its supply chain, and lower expected long-term cost of goods. Juno plans to operate the acquired company, which employs 23 scientists, engineers, and other personnel, as a wholly-owned German subsidiary under the name Juno Therapeutics GmbH.

Since its founding in 2005, Stage Cell has been translating innovative and unique science and technology into cell therapeutics. The company´s next generation cell isolation and expansion technology platforms are based on fully reversible reagents that enable the advanced isolation and expansion of T-cells during the manufacturing process.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member